Everything below concerns receptor agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
More recent data has not confirmed this association: it is thought that the disease itself is linked with a slightly higher background risk of malignancy. Ongoing data analysis on large patient populations continues in this area.
=== Zeolitic imidazolate frameworks (ZIFs) === Several different mechanical phenomena have been observed in zeolitic imidazolate frameworks (ZIFs), the most widely studied MOF for mechanical properties due to their many similarities to zeolites. General trends for the ZIF family are the tendency of the Young's modulus and hardness of the ZIFs to decrease as the accessible pore volume increases. The bulk moduli of ZIF-62 series increase with the increasing of benzoimidazolate (bim−) concentration. ZIF-62 shows a continuous phase transition from open pore (op) to close pore (cp) phase when bim− concentration is over 0.35 per formular unit. The accessible pore size and volume of ZIF-62-bim0.35 can be precisely tuned by applying adequate pressures. Another study has shown that under hydrostatic loading in solvent the ZIF-8 material expands as opposed to contracting. This is a result of hyperfilling of the internal pores with solvent. A computational study demonstrated that ZIF-4 and ZIF-8 materials undergo a shear softening mechanism with amorphizing (at ~ 0.34 GPa) of the material under hydrostatic loading, while still possessing a bulk modulus on the order of 6.5 GPa. Additionally, the ZIF-4 and ZIF-8 MOFs are subject to many pressure dependent phase transitions.
In May 2014, researchers announced that they had successfully introduced two new artificial nucleotides into bacterial DNA, and by including individual artificial nucleotides in the culture media, were able to induce amplification of the plasmids containing the artificial nucleotides by a factor of 2 × 107 (24 doublings); they did not create mRNA or proteins able to use the artificial nucleotides.
called the plasticity index that could be used to determine whether contact would be elastic or plastic. The Greenwood-Williamson model requires knowledge of two statistically dependent quantities; the standard deviation of the surface roughness and the curvature of the asperity peaks. An alternative definition of the plasticity index has been given by Mikic. Yield occurs when the pressure is greater than the uniaxial yield stress. Since the yield stress is proportional to the indentation hardness
=== "Moonlighting" === In addition to its intracellular role as the major actin-sequestering molecule in cells of many multicellular animals, thymosin β4 shows a remarkably diverse range of effects when present in the fluid surrounding animal tissue cells. Taken together, these effects suggest that thymosin has a general role in tissue regeneration. This has suggested a variety of possible therapeutic applications, and several have now been extended to animal models and human clinical trials. It is considered unlikely that thymosin β4 exerts all these effects via intracellular sequestration of G-actin. This would require its uptake by cells, and moreover, in most cases the cells affected already have substantial intracellular concentrations. The diverse activities related to tissue repair may depend on interactions with receptors quite distinct from actin and possessing extracellular ligand-binding domains. Such multi-tasking by, or "partner promiscuity" of, proteins has been referred to as protein moonlighting. Proteins such as thymosins which lack stable folded structure in aqueous solution, are known as intrinsically unstructured proteins (IUPs). Because IUPs acquire specific folded structures only on binding to their partner proteins, they offer special possibilities for interaction with multiple partners. A candidate extracellular receptor of high affinity for thymosin β4 is the β subunit of cell surface-located ATP synthase, which would allow extracellular thymosin to signal via a purinergic receptor.
Sources: en.wikipedia.org
=== Travels === Jung emerged from his period of isolation in the late 1910s with the publication of several journal articles, followed in 1921 with Psychological Types, one of his most influential books. There followed a decade of active publication, interspersed with overseas travels. In addition to his international travels, in 1922, he bought some land at Bollingen in Zürich, where he built a tower. He would continue to build other additions to the building, constructing an "architectural mandala".
The two substrates of this enzyme are glycerol and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are glycerone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is glycerol:NADP+ 2-oxidoreductase (glycerone-forming). Other names in common use include dihydroxyacetone reductase, dihydroxyacetone (reduced nicotinamide adenine dinucleotide, phosphate) reductase, dihydroxyacetone reductase (NADPH), DHA oxidoreductase, and glycerol 2-dehydrogenase (NADP+). This enzyme participates in glycerolipid metabolism.
The Treuhandanstalt (German: [ˈtʁɔɪ̯hantˌʔanʃtalt] , "Trust agency"), colloquially referred to as Treuhand, was a government agency of the German Democratic Republic (East Germany) from June to October 1990 and reunified Germany from 1990 to 1994, responsible for the reprivatisation/privatisation of the Volkseigene Betriebe (VEBs) and other state-owned enterprises in East Germany. The Treuhand was established by the Volkskammer of East Germany during Die Wende, to oversee the restructure and sale of about 8,500 state-owned companies with over four million employees – the world's largest industrial enterprise, controlling everything from steel works to the Babelsberg Studios. It inherited the assets of the Socialist Unity Party of Germany and other East German government agencies after German reunification in October 1990. The Treuhand was dissolved by the Federal Government of Germany on 1 January 1995 and reconstituted as the Federal Agency for Special Tasks Related to Unification (Bundesanstalt für vereinigungsbedingte Sonderaufgaben) which was active until 2000. The Treuhand has faced criticism and opposition for its handling of the privatisation process in the former East Germany, particularly for excessive liquidation and the resulting layoffs. On 1 April 1991, Treuhand chairman Detlev Karsten Rohwedder was assassinated by the Red Army Faction (RAF), a West German far-left terrorist group sponsored and supported by the East German Stasi. The shooter has never been identified.
Due to his insecurity about his Persian heritage, he distanced himself from his culture and bullied others to avoid getting bullied himself, though he has regrets about this. He has naturally black hair that he dyes blond for most of the book, light brown skin, and black eyes. He is homosexual. Anna Lightwood — regarded as a bit of a bohemian, Anna is a quite popular with the ladies but disapproved of by the older generation for her lifestyle choices and for dressing like a man. She acts as an older sister to the others and often does her best to look out for and assist them. She is genderqueer, and dates women, though she does not like to commit after having her heart broken by Ariadne Bridgestock, her first love. Like Matthew, Anna is very stylish. She has black hair and blue eyes. Ariadne Bridgestock — the adopted daughter of the Inquisitor. She was engaged to Charles Fairchild, though he later breaks it off. Ariadne is secretly a lesbian and has a history with Anna. She is determined to win Anna back after initially losing her due to her engagement with Charles. Grace Blackthorn — the mysterious adopted daughter of Tatiana Blackthorn whom James is in love with. She seems meek and frail but is actually quite cold and calculating. Tatiana Blackthorn — a maddened woman who seeks revenge and to resurrect her dead son. The London Enclave — governing body of the local Shadowhunters, which consists of Will Herondale, Tessa Gray, Charles Fairchild, Henry Branwell, Gabriel Lightwood, Gideon Lightwood, Sophie Collins, and Cecily Herondale.
Sources: en.wikipedia.org
In botany, apical dominance is the phenomenon whereby the main, central stem of the plant is dominant over (i.e., grows more strongly than) other side stems; on a branch the main stem of the branch is further dominant over its own side twigs. Plant physiology describes apical dominance as the control exerted by the terminal bud (and shoot apex) over the outgrowth of lateral buds.
== Summary table for numbers of each class of nuclides == This is a summary table from List of nuclides. Numbers are not exact and may change slightly in the future, as nuclides are observed to be radioactive, or new half-lives are determined to some precision.
=== A10BX Other blood glucose lowering drugs, excluding insulins === A10BX01 Guar gum A10BX02 Repaglinide A10BX03 Nateglinide A10BX05 Pramlintide A10BX06 Benfluorex A10BX08 Mitiglinide A10BX15 Imeglimin A10BX16 Tirzepatide A10BX17 Carfloglitazar A10BX18 Dorzagliatin
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
The lyophilized powder is dissolved in a suitable solvent, often sterile water or a buffered diluent, with gentle mixing rather than vigorous shaking. Foaming and shear should be avoided because they can promote aggregation. The resulting solution is then stored cold and protected from light.